請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90705
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃義侑 | zh_TW |
dc.contributor.advisor | Yi-You Huang | en |
dc.contributor.author | 許煜婕 | zh_TW |
dc.contributor.author | Yu-Chieh Hsu | en |
dc.date.accessioned | 2023-10-03T17:15:47Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-10-03 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-07-13 | - |
dc.identifier.citation | (1) Polack, F. P.; Thomas, S. J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J. L.; Marc, G. P.; Moreira, E. D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383 (27), 2603-2615, Article. DOI: 10.1056/NEJMoa2034577.
(2) Baden, L. R.; El Sahly, H. M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S. A.; Rouphael, N.; Creech, C. B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384 (5), 403-416, Article. DOI: 10.1056/NEJMoa2035389. (3) Rohner, E.; Yang, R.; Foo, K. S.; Goedel, A.; Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 2022, 40 (11), 1586-1600, Review. DOI: 10.1038/s41587-022-01491-z. (4) Gebre, M. S.; Rauch, S.; Roth, N.; Yu, J. Y.; Chandrashekar, A.; Mercado, N. B.; He, X.; Liu, J. Y.; McMahan, K.; Martinot, A.; et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature 2022, 601 (7893), 410-+, Article. DOI: 10.1038/s41586-021-04231-6. (5) de Alwis, R.; Gan, E. S.; Chen, S. W.; Leong, Y. S.; Tan, H. C.; Zhang, S. L.; Yau, C.; Low, J. G. H.; Kalimuddin, S.; Matsuda, D.; et al. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Molecular Therapy 2021, 29 (6), 1970-1983, Article. DOI: 10.1016/j.ymthe.2021.04.001. (6) Arcturus Therapeutics. Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study. 2022. https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-announces-self-amplifying-covid-19-mrna-vaccine (accessed 2023 Apr 11). (7) Huang, X. G.; Kong, N.; Zhang, X. C.; Cao, Y. H.; Langer, R.; Tao, W. The landscape of mRNA nanomedicine. Nat. Med. 2022, 28 (11), 2273-2287, Review. DOI: 10.1038/s41591-022-02061-1. (8) Puccetti, M.; Schoubben, A.; Giovagnoli, S.; Ricci, M. Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age? Int. J. Mol. Sci. 2023, 24 (3), 11, Review. DOI: 10.3390/ijms24032218. (9) Gu, Y. Z.; Duan, J. Y.; Yang, N.; Yang, Y. X.; Zhao, X. mRNA vaccines in the prevention and treatment of diseases. MedComm 2022, 3 (3), 31, Review. DOI: 10.1002/mco2.167. (10) Schiller, J. T. L., D.R. An Introduction to Virus Infections and Human Cancer. In Recent Results in Cancer Research, Wu, T. C., MH.; Jeang, KT. Ed.; Vol. 217; Springer, Cham, 2020; pp 1-11. (11) Lorentzen, C. L.; Haanen, J. B.; Met, O.; Svane, I. M. Clinical advances and ongoing trials of mRNA vaccines for cancer treatment. Lancet Oncol. 2022, 23 (10), E450-E458, Review. (12) Hollingsworth, R. E.; Jansen, K. Turning the corner on therapeutic cancer vaccines. npj Vaccines 2019, 4, 10, Review. DOI: 10.1038/s41541-019-0103-y. (13) Xie, N.; Shen, G. B.; Gao, W.; Huang, Z.; Huang, C. H.; Fu, L. Neoantigens: promising targets for cancer therapy. Signal Transduction and Targeted Therapy 2023, 8 (1), 38, Review. DOI: 10.1038/s41392-022-01270-x. (14) Guo, Y. G.; Lei, K. W.; Tang, L. Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy. Front. Immunol. 2018, 9, 8, Review. DOI: 10.3389/fimmu.2018.01499. (15) Lang, F.; Schrors, B.; Lower, M.; Tureci, O.; Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nature Reviews Drug Discovery 2022, 21 (4), 261-282, Review. DOI: 10.1038/s41573-021-00387-y. (16) Lancaster, E. M.; Jablons, D.; Kratz, J. R. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development. Genet. Test. Mol. Biomark. 2020, 24 (2), 59-66, Article. DOI: 10.1089/gtmb.2018.0211. (17) Blass, E.; Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 2021, 18 (4), 215-229, Review. DOI: 10.1038/s41571-020-00460-2. (18) Merck. Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA® (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial. 2022. https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/ (accessed 2023 Apr 17). (19) Barbier, A. J.; Jiang, A. Y. J.; Zhang, P.; Wooster, R.; Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 2022, 40 (6), 840-854, Review. DOI: 10.1038/s41587-022-01294-2. (20) Qin, S. G.; Tang, X. S.; Chen, Y. T.; Chen, K. P.; Fan, N.; Xiao, W.; Zheng, Q.; Li, G. H.; Teng, Y. Q.; Wu, M.; et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduction and Targeted Therapy 2022, 7 (1), 35, Review. DOI: 10.1038/s41392-022-01007-w. (21) Vavilis, T.; Stamoula, E.; Ainatzoglou, A.; Sachinidis, A.; Lamprinou, M.; Dardalas, I.; Vizirianakis, I. S. mRNA in the Context of Protein Replacement Therapy. Pharmaceutics 2023, 15 (1), 19, Review. DOI: 10.3390/pharmaceutics15010166. (22) Hajj, K. A.; Whitehead, K. A. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat. Rev. Mater. 2017, 2 (10), 17, Review. DOI: 10.1038/natrevmats.2017.56. (23) Khan, M. A. B.; Hashim, M. J.; Mustafa, H.; Baniyas, M. Y.; Al Suwaidi, S.; AlKatheeri, R.; Alblooshi, F. M. K.; Almatrooshi, M.; Alzaabi, M. E. H.; Al Darmaki, R. S.; et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus 2020, 12 (7), 12, Article. DOI: 10.7759/cureus.9349. (24) Yla-Herttuala, S.; Baker, A. H. Cardiovascular Gene Therapy: Past, Present, and Future. Molecular Therapy 2017, 25 (5), 1095-1106, Review. DOI: 10.1016/j.ymthe.2017.03.027. (25) Anttila, V.; Saraste, A.; Knuuti, J.; Jaakkola, P.; Hedman, M.; Svedlund, S.; Lagerstrom-Fermer, M.; Kjaer, M.; Jeppsson, A.; Gan, L. M. Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial. Mol.Ther.-Methods Clin. Dev. 2020, 18, 464-472, Article. DOI: 10.1016/j.omtm.2020.05.030. (26) Lopes-Pacheco, M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Frontiers in Pharmacology 2020, 10, 29, Review. DOI: 10.3389/fphar.2019.01662. (27) Kreda, S. M.; Davis, C. W.; Rose, M. C. CFTR, Mucins, and Mucus Obstruction in Cystic Fibrosis. Cold Spring Harb. Perspect. Med. 2012, 2 (9), 32, Article. DOI: 10.1101/cshperspect.a009589. (28) Robinson, E.; MacDonald, K. D.; Slaughter, K.; McKinney, M.; Patel, S.; Sun, C.; Sahay, G. Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. Molecular Therapy 2018, 26 (8), 2034-2046, Article. DOI: 10.1016/j.ymthe.2018.05.014. (29) Roh, E. H.; Fromen, C. A.; Sullivan, M. O. Inhalable mRNA vaccines for respiratory diseases: a roadmap. Curr. Opin. Biotechnol. 2022, 74, 6, Review. DOI: 10.1016/j.copbio.2021.10.017. (30) Gomez-Aguado, I.; Rodriguez-Castejon, J.; Vicente-Pascual, M.; Rodriguez-Gascon, A.; Solinis, M. A.; del Pozo-Rodriguez, A. Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives. Nanomaterials 2020, 10 (2), 42, Review. DOI: 10.3390/nano10020364. (31) Vertex Pharmaceuticals Incorporated. Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA. 2022. https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-investigational-new-drug-ind-application-vx-522 (accessed 2023 Apr 21). (32) Chaudhary, N.; Weissman, D.; Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 2021, 20 (11), 817-838, Review. DOI: 10.1038/s41573-021-00283-5. (33) Yan, Y.; Liu, X. Y.; Lu, A.; Wang, X. Y.; Jiang, L. X.; Wang, J. C. Non-viral vectors for RNA delivery. Journal of Controlled Release 2022, 342, 241-279, Article. DOI: 10.1016/j.jconrel.2022.01.008. (34) Ulkoski, D.; Bak, A.; Wilson, J. T.; Krishnamurthy, V. R. Recent advances in polymeric materials for the delivery of RNA therapeutics. Expert Opinion on Drug Delivery 2019, 16 (11), 1149-1167, Review. DOI: 10.1080/17425247.2019.1663822. (35) Paunovska, K.; Loughrey, D.; Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nature Reviews Genetics 2022, 23 (5), 265-280, Review. DOI: 10.1038/s41576-021-00439-4. (36) Carvalho, M.; Sepodes, B.; Martins, A. P. Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework. Front. Med. 2017, 4, 18, Review. DOI: 10.3389/fmed.2017.00182. (37) Yin, H.; Kanasty, R. L.; Eltoukhy, A. A.; Vegas, A. J.; Dorkin, J. R.; Anderson, D. G. Non-viral vectors for gene-based therapy. Nature Reviews Genetics 2014, 15 (8), 541-555, Review. DOI: 10.1038/nrg3763. (38) Malone, R. W.; Felgner, P. L.; Verma, I. M. Cationic liposome-mediated RNA transfection. Proc. Natl. Acad. Sci. U. S. A. 1989, 86 (16), 6077-6081, Article. DOI: 10.1073/pnas.86.16.6077. (39) Zohra, F. T.; Chowdhury, E. H.; Tada, S.; Hoshiba, T.; Akaike, T. Effective delivery with enhanced translational activity synergistically accelerates mRNA-based transfection. Biochem. Biophys. Res. Commun. 2007, 358 (1), 373-378, Article. DOI: 10.1016/j.bbrc.2007.04.059. (40) Kauffman, K. J.; Webber, M. J.; Anderson, D. G. Materials for non-viral intracellular delivery of messenger RNA therapeutics. Journal of Controlled Release 2016, 240, 227-234, Article. DOI: 10.1016/j.jconrel.2015.12.032. (41) Koltover, I.; Salditt, T.; Radler, J. O.; Safinya, C. R. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 1998, 281 (5373), 78-81, Article. DOI: 10.1126/science.281.5373.78. (42) Hattori, Y.; Suzuki, S.; Kawakami, S.; Yamashita, F.; Hashida, M. The role of dioleoylphosphaticlylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route. Journal of Controlled Release 2005, 108 (2-3), 484-495, Article. DOI: 10.1016/j.jconrel.2005.08.012. (43) Wasungu, L.; Hoekstra, D. Cationic lipids, lipoplexes and intracellular delivery of genes. Journal of Controlled Release 2006, 116 (2), 255-264, Article; Proceedings Paper. DOI: 10.1016/j.jconrel.2006.06.024. (44) Wolff, J. A.; Rozema, D. B. Breaking the bonds: Non-viral vectors become chemically dynamic. Molecular Therapy 2008, 16 (1), 8-15, Review. DOI: 10.1038/sj.mt.6300326. (45) Islam, M. A.; Reesor, E. K. G.; Xu, Y. J.; Zope, H. R.; Zetter, B. R.; Shi, J. J. Biomaterials for mRNA delivery. Biomater. Sci. 2015, 3 (12), 1519-1533, Review. DOI: 10.1039/c5bm00198f. (46) Bao, Y. J.; Jin, Y.; Chivukula, P.; Zhang, J.; Liu, Y.; Liu, J.; Clamme, J. P.; Mahato, R. I.; Ng, D.; Ying, W. B.; et al. Effect of PEGylation on Biodistribution and Gene Silencing of siRNA/Lipid Nanoparticle Complexes. Pharm. Res. 2013, 30 (2), 342-351, Article. DOI: 10.1007/s11095-012-0874-6. (47) Barenholz, Y. Doxil (R) - The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release 2012, 160 (2), 117-134, Review. DOI: 10.1016/j.jconrel.2012.03.020. (48) Zhang, X. P.; Goel, V.; Robbie, G. J. Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis. J. Clin. Pharmacol. 2020, 60 (5), 573-585, Article. DOI: 10.1002/jcph.1553. (49) Zhang, Y. B.; Sun, C. Z.; Wang, C.; Jankovic, K. E.; Dong, Y. Z. Lipids and Lipid Derivatives for RNA Delivery. Chemical Reviews 2021, 121 (20), 12181-12277, Review. DOI: 10.1021/acs.chemrev.1c00244. (50) Patel, S.; Kim, J.; Herrera, M.; Mukherjee, A.; Kabanov, A. V.; Sahay, G. Brief update on endocytosis of nanomedicines. Advanced Drug Delivery Reviews 2019, 144, 90-111, Review. DOI: 10.1016/j.addr.2019.08.004. (51) Yang, S. T.; Kreutzberger, A. J. B.; Lee, J.; Kiessling, V.; Tamm, L. K. The role of cholesterol in membrane fusion. Chem. Phys. Lipids 2016, 199, 136-143, Article. DOI: 10.1016/j.chemphyslip.2016.05.003. (52) Teixeira, H. F.; Bruxel, F.; Fraga, M.; Schuh, R. S.; Zorzi, G. K.; Matte, U.; Fattal, E. Cationic nanoemulsions as nucleic acids delivery systems. International Journal of Pharmaceutics 2017, 534 (1-2), 356-367, Review. DOI: 10.1016/j.ijpharm.2017.10.030. (53) Brito, L. A.; Chan, M.; Shaw, C. A.; Hekele, A.; Carsillo, T.; Schaefer, M.; Archer, J.; Seubert, A.; Otten, G. R.; Beard, C. W.; et al. A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines. Molecular Therapy 2014, 22 (12), 2118-2129, Article. DOI: 10.1038/mt.2014.133. (54) Nitika; Wei, J.; Hui, A. M. The Delivery of mRNA Vaccines for Therapeutics. Life-Basel 2022, 12 (8), 16, Review. DOI: 10.3390/life12081254. (55) Bus, T.; Traeger, A.; Schubert, U. S. The great escape: how cationic polyplexes overcome the endosomal barrier. Journal of Materials Chemistry B 2018, 6 (43), 16, Review. DOI: 10.1039/c8tb00967h. (56) Nel, A. E.; Madler, L.; Velegol, D.; Xia, T.; Hoek, E. M. V.; Somasundaran, P.; Klaessig, F.; Castranova, V.; Thompson, M. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 2009, 8 (7), 543-557, Review. DOI: 10.1038/nmat2442. (57) Lv, H. T.; Zhang, S. B.; Wang, B.; Cui, S. H.; Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. Journal of Controlled Release 2006, 114 (1), 100-109, Review. DOI: 10.1016/j.jconrel.2006.04.014. (58) Breunig, M.; Lungwitz, U.; Liebl, R.; Goepferich, A. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (36), 14454-14459, Article. DOI: 10.1073/pnas.0703882104. (59) Tan, L.; Zheng, T.; Li, M.; Zhong, X. F.; Tang, Y.; Qin, M.; Sun, X. Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates. Drug Delivery and Translational Research 2020, 10 (3), 678-689, Article. DOI: 10.1007/s13346-020-00725-4. (60) Ke, X. Y.; Shelton, L.; Hu, Y. Z.; Zhu, Y. N.; Chow, E.; Tang, H. Y.; Santos, J. L.; Mao, H. Q. Surface-Functionalized PEGylated Nanoparticles Deliver Messenger RNA to Pulmonary Immune Cells. Acs Applied Materials & Interfaces 2020, 12 (32), 35835-35844, Article. DOI: 10.1021/acsami.0c08268. (61) Gao, Y. S.; Huang, J. Y.; Ahern, J. O.; Cutlar, L.; Zhou, D. Z.; Lin, F. H.; Wang, W. X. Highly Branched Poly(beta-amino esters) for Non-Viral Gene Delivery: High Transfection Efficiency and Low Toxicity Achieved by Increasing Molecular Weight. Biomacromolecules 2016, 17 (11), 3640-3647, Article. DOI: 10.1021/acs.biomac.6b01120. (62) Liu, Y.; Li, Y. F.; Keskin, D.; Shi, L. Q. Poly(beta-Amino Esters): Synthesis, Formulations, and Their Biomedical Applications. Advanced Healthcare Materials 2019, 8 (2), 24, Review. DOI: 10.1002/adhm.201801359. (63) Patel, A. K.; Kaczmarek, J. C.; Bose, S.; Kauffman, K. J.; Mir, F.; Heartlein, M. W.; DeRosa, F.; Langer, R.; Anderson, D. G. Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium. Adv. Mater. 2019, 31 (8), 7, Article. DOI: 10.1002/adma.201805116. (64) Miyata, K.; Oba, M.; Nakanishi, M.; Fukushima, S.; Yamasaki, Y.; Koyama, H.; Nishiyama, N.; Kataoka, K. Polyplexes from Poly(aspartamide) Bearing 1,2-Diaminoethane Side Chains Induce pH-Selective, Endosomal Membrane Destabilization with Amplified Transfection and Negligible Cytotoxicity. Journal of the American Chemical Society 2008, 130 (48), 16287-16294, Article. DOI: 10.1021/ja804561g. (65) Baba, M.; Itaka, K.; Kondo, K.; Yamasoba, T.; Kataoka, K. Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles. Journal of Controlled Release 2015, 201, 41-48, Article. DOI: 10.1016/j.jconrel.2015.01.017. (66) Scheicher, B.; Schachner-Nedherer, A. L.; Zimmer, A. Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting. Eur. J. Pharm. Sci. 2015, 75, 54-59, Review. DOI: 10.1016/j.ejps.2015.04.009. (67) Amos, H. Protamine Enhancement of RNA Uptake by Cultured Chick Cells. Biochem. Biophys. Res. Commun. 1961, 5 (1), 1-&, Article. DOI: 10.1016/0006-291x(61)90069-9. (68) Jarzebska, N. T.; Mellett, M.; Frei, J.; Kundig, T. M.; Pascolo, S. Protamine-Based Strategies for RNA Transfection. Pharmaceutics 2021, 13 (6), 14, Review. DOI: 10.3390/pharmaceutics13060877. (69) Sasso, J. M.; Ambrose, B. J. B.; Tenchov, R.; Datta, R. S.; Basel, M. T.; DeLong, R. K.; Zhou, Q. Q. A. The Progress and Promise of RNA Medicine?An Arsenal ofTargeted Treatments. J. Med. Chem. 2022, 65 (10), 6975-7015, Article. DOI: 10.1021/acs.jmedchem.2c00024. (70) Fotin-Mleczek, M.; Duchardt, K. M.; Lorenz, C.; Pfeiffer, R.; Ojkic-Zrna, S.; Probst, J.; Kallen, K. J. Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity. J. Immunother. 2011, 34 (1), 1-15, Article. DOI: 10.1097/CJI.0b013e3181f7dbe8. (71) Yokoo, H.; Oba, M.; Uchida, S. Cell-Penetrating Peptides: Emerging Tools for mRNA Delivery. Pharmaceutics 2022, 14 (1), 13, Review. DOI: 10.3390/pharmaceutics14010078. (72) Guidotti, G.; Brambilla, L.; Rossi, D. Cell-Penetrating Peptides: From Basic Research to Clinics. Trends Pharmacol. Sci. 2017, 38 (4), 406-424, Review. DOI: 10.1016/j.tips.2017.01.003. (73) Ruseska, I.; Zimmer, A. Internalization mechanisms of cell-penetrating peptides. Beilstein J. Nanotechnol. 2020, 11, 101-123, Review. DOI: 10.3762/bjnano.11.10. (74) Udhayakumar, V. K.; De Beuckelaer, A.; McCaffrey, J.; McCrudden, C. M.; Kirschman, J. L.; Vanover, D.; Van Hoecke, L.; Roose, K.; Deswarte, K.; De Geest, B. G.; et al. Arginine-Rich Peptide-Based mRNA Nanocomplexes Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic Organization of the Peptide. Advanced Healthcare Materials 2017, 6 (13), 13, Article. DOI: 10.1002/adhm.201601412. (75) Kumar, R.; Santa Chalarca, C. F.; Bockman, M. R.; Van Bruggen, C.; Grimme, C. J.; Dalal, R. J.; Hanson, M. G.; Hexum, J. K.; Reineke, T. M. Polymeric Delivery of Therapeutic Nucleic Acids. Chemical Reviews 2021, 121 (18), 11527-11652, Review. DOI: 10.1021/acs.chemrev.0c00997. (76) Kowalski, P. S.; Rudra, A.; Miao, L.; Anderson, D. G. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Molecular Therapy 2019, 27 (4), 710-728, Review. DOI: 10.1016/j.ymthe.2019.02.012. (77) Li, S. D.; Huang, L. Surface-modified LPD nanoparticles for tumor targeting. In Oligonucleotide Therapeutics, Tuschl, T., Rossi, J. Eds.; Annals of the New York Academy of Sciences, Vol. 1082; Blackwell Publishing, 2006; pp 1-8. (78) Wang, Y. H.; Su, H. H.; Yang, Y.; Hu, Y. X.; Zhang, L.; Blancafort, P.; Huang, L. Systemic Delivery of Modified mRNA Encoding Herpes Simplex Virus 1 Thymidine Kinase for Targeted Cancer Gene Therapy. Molecular Therapy 2013, 21 (2), 358-367, Article. DOI: 10.1038/mt.2012.250. (79) Palama, I. E.; Cortese, B.; D'Amone, S.; Gigli, G. mRNA delivery using non-viral PCL nanoparticles. Biomater. Sci. 2015, 3 (1), 144-151, Article. DOI: 10.1039/c4bm00242c. (80) Su, X. F.; Fricke, J.; Kavanagh, D. G.; Irvine, D. J. In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles. Molecular Pharmaceutics 2011, 8 (3), 774-787, Article. DOI: 10.1021/mp100390w. (81) Islam, M. A.; Xu, Y. J.; Tao, W.; Ubellacker, J. M.; Lim, M.; Aum, D.; Lee, G. Y.; Zhou, K.; Zope, H.; Yu, M.; et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat. Biomed. Eng 2018, 2 (11), 850-864, Article. DOI: 10.1038/s41551-018-0284-0. (82) Wei, W.; Sun, J.; Guo, X. Y.; Chen, X.; Wang, R.; Qiu, C.; Zhang, H. T.; Pang, W. H.; Wang, J. C.; Zhang, Q. Microfluidic-Based Holonomic Constraints of siRNA in the Kernel of Lipid/Polymer Hybrid Nanoassemblies for Improving Stable and Safe In Vivo Delivery. Acs Applied Materials & Interfaces 2020, 12 (13), 14839-14854, Article. DOI: 10.1021/acsami.9b22781. (83) Mai, Y. P.; Guo, J. S.; Zhao, Y.; Ma, S. J.; Hou, Y. H.; Yang, J. H. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cell. Immunol. 2020, 354, 9, Article. DOI: 10.1016/j.cellimm.2020.104143. (84) Li, H. M.; Jiang, H.; Zhao, M. N.; Fu, Y.; Sun, X. Intracellular redox potential-responsive micelles based on polyethylenimine-cystamine-poly(epsilon-caprolactone) block copolymer for enhanced miR-34a delivery. Polymer Chemistry 2015, 6 (11), 1952-1960, Article. DOI: 10.1039/c4py01623h. (85) Carrasco, M. J.; Alishetty, S.; Alameh, M. G.; Said, H.; Wright, L.; Paige, M.; Soliman, O.; Weissman, D.; Cleveland, T. E.; Grishaev, A.; et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun. Biol. 2021, 4 (1), 15, Article. DOI: 10.1038/s42003-021-02441-2. (86) Lee, J.; Vogt, C. E.; McBrairty, M.; Al-Hashimi, H. M. Influence of Dimethylsulfoxide on RNA Structure and Ligand Binding. Anal. Chem. 2013, 85 (20), 9692-9698, Article. DOI: 10.1021/ac402038t. (87) Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8 (2), 129-138, Review. DOI: 10.1038/nrd2742. (88) Sahin, U.; Kariko, K.; Tureci, O. mRNA-based therapeutics - developing a new class of drugs. Nat. Rev. Drug Discov. 2014, 13 (10), 759-780, Review. DOI: 10.1038/nrd4278. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90705 | - |
dc.description.abstract | 在嚴重特殊傳染性肺炎疫情爆發後,大眾對於mRNA疫苗的關注度大幅上升,mRNA的各項應用及遞送技術也受到各界重視。除了感染性疾病疫苗外,mRNA也被應用於癌症治療及預防,以及蛋白質替代療法等新興領域,對於許多疾病皆具有應用潛力。
本研究使用編碼增強型綠色螢光蛋白(enhanced green fluorescent protein, EGFP)之mRNA,探討脂質/高分子複合奈米粒子及脂質複合奈米粒子二種系統,期望透過不同遞送材料及組成的測試,開發出合成簡易、成本較低的mRNA載體平台。在脂質/高分子複合奈米粒子部分,選用PCL-PEI作為高分子材料,結合PCL的生物降解性及PEI帶正電可與帶負電之核酸分子結合的特性,再經過脂質包覆提升親脂性,增進細胞攝取。然而目前在小鼠胚胎成纖維細胞株NIH-3T3及人類胚胎腎細胞株HEK-293皆未觀察到綠色螢光表現,推測可能原因包含溶劑DMSO對RNA結構的破壞性及形成粒子粒徑過大。而在脂質複合奈米粒子方面,進行不同脂質組成的測試,透過奈米粒子之mRNA有效包覆率及對HEK-293細胞的轉染效率等分析,找出最佳化製備條件為所含脂質總濃度次高、正電荷脂質比例最高的LNP6組別(各成分莫耳比例為37.5 % DOTAP、43.125% DOPE、3.75% Stearylamine、2.1875 % SM-102、12.5 % Cholesterol、0.9375 % DSPE-PEG2000),接著測試以魚精蛋白先行與mRNA縮合,再透過該條件之脂質組成包覆,發現與僅以脂質包覆的組別相比,粒徑較為均一,但細胞轉染效率較低,推測為魚精蛋白與mRNA之間的結合過於緊密所致。綜合而言,本研究探討之不同系統的mRNA載體平台中,以脂質複合奈米粒子的LNP6組別效果最佳,可以此為基礎,開發出合成簡易、成本較低的mRNA載體平台。 | zh_TW |
dc.description.abstract | After the COVID-19 outbreak, there has been a significant increase in public interest in mRNA vaccines. The attention has extended to various applications and delivery technologies of mRNA. Apart from vaccines for infectious diseases, mRNA has also found utility in emerging fields such as cancer treatment and prevention, as well as protein replacement therapy. It holds immense potential for application in numerous diseases.
This study aimed to investigate two systems of lipid/polymer composite nanoparticles and lipid composite nanoparticles using mRNA encoding enhanced green fluorescent protein (EGFP). The goal was to develop an mRNA carrier platform that is easy to synthesize and cost-effective by testing different delivery materials and compositions. In the case of lipid/polymer hybrid nanoparticles, PCL-PEI was chosen as the polymer material due to the biodegradability of PCL and the positive charge of PEI, which allows it to bind to negatively charged nucleic acid molecules. Lipids were then coated onto the particles to enhance lipophilicity and improve cellular uptake. However, no green fluorescence was observed in the mouse embryonic fibroblast cell line NIH-3T3 or the human embryonic kidney cell line HEK-293. Possible reasons include the destructive effect of the solvent DMSO on the RNA structure and the excessive size of the particles formed. As for lipid hybrid nanoparticles, different lipid compositions were tested. The encapsulation efficiency of nanoparticles and the transfection efficiency of HEK-293 cells were analyzed to identify the optimal lipid composition, and we found that with second highest total lipid concentration and highest ratio of positively charged lipids, LNP6, composed of 37.5 % DOTAP, 43.125% DOPE, 3.75% Stearylamine, 2.1875 % SM-102, 12.5 % Cholesterol and 0.9375 % DSPE-PEG2000, exhibited the best performance. Subsequently, the composition of LNP6 was selected to test the influence of protamine. We first condensed protamine with mRNA and then coated it with the specified lipid composition. The results showed that compared to the group only composed of lipids, the particle size was relatively uniform. However, the cell transfection efficiency was low, possibly due to the excessively strong binding between protamine and mRNA. In conclusion, among the different mRNA carrier platforms discussed in this study, the LNP6 group of lipid hybrid nanoparticles demonstrated the most promising results. This finding paves the way for the development of an mRNA carrier platform that is simple to synthesize and cost-effective. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-10-03T17:15:47Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-10-03T17:15:47Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 摘要 iii Abstract iv 目錄 vi 圖目錄 ix 表目錄 xi 第一章 緒論 1 1.1 mRNA應用 1 1.1.1 感染性疾病疫苗 2 1.1.2 癌症疫苗 3 1.1.3 蛋白質替代療法 5 1.2 mRNA載體平台 6 1.2.1 脂質系統 (Lipid-based systems) 8 1.2.2 高分子系統 (Polymeric systems) 10 1.2.3 胜肽系統 (Peptide-based systems) 11 1.2.4 複合系統 (Hybrid systems) 13 第二章 研究概述 15 2.1 研究背景與動機 15 2.2 方法簡述 16 2.3 實驗架構 17 第三章 實驗材料與方法 18 3.1 實驗藥品 18 3.2 實驗儀器 20 3.3 材料製備 21 3.3.1 PCL-PEI合成 21 3.3.2 mRNA脂質/高分子複合奈米粒子之製備(逐滴加入法) 22 3.3.3 mRNA脂質/高分子複合奈米粒子之製備(T字形混合法) 23 3.3.4 mRNA脂質複合奈米粒子之製備 24 3.3.5 mRNA脂質/魚精蛋白複合奈米粒子之製備 25 3.4 材料分析 26 3.4.1 複合奈米粒子之基本性質鑑定 26 3.4.1.1 動態光散射分析 (Dynamic Light Scattering, DLS) 26 3.4.1.2 mRNA有效包覆率測定 27 3.4.2 體外試驗 28 3.4.2.1 細胞存活率試驗 28 3.4.2.2 細胞轉染效率分析 28 3.4.2.3 表達綠色螢光蛋白之細胞螢光影像 29 3.4.2.4 以倒立式共軛焦顯微鏡拍攝之細胞螢光影像 29 3.5 統計分析 29 第四章 結果與討論 30 4.1 脂質/高分子複合奈米粒子 30 4.1.1 PCL-PEI特性鑑定 30 4.1.2 逐滴加入法 30 4.1.2.1 脂質/高分子複合奈米粒子之基本性質鑑定 30 4.1.2.1.1 粒徑及介面電位分析 30 4.1.2.2 脂質/高分子複合奈米粒子之體外試驗 31 4.1.2.2.1 細胞存活率 31 4.1.2.2.2 細胞轉染效率 32 4.1.3 T字形混合法 33 4.1.3.1 脂質/高分子複合奈米粒子之體外試驗 33 4.1.3.1.1 細胞存活率 33 4.1.3.1.2 細胞轉染效率 34 4.1.3.2 脂質/高分子複合奈米粒子之基本性質鑑定 35 4.1.2.2.1 粒徑及介面電位分析 35 4.1.4 改良之T字形混合法 35 4.1.4.1 脂質/高分子複合奈米粒子之基本性質鑑定 35 4.1.4.1.1 粒徑及介面電位分析 35 4.2 脂質複合奈米粒子 36 4.2.1 不同組成比例之脂質複合奈米粒子 36 4.2.1.1 脂質複合奈米粒子之基本性質鑑定 36 4.2.1.1.1 粒徑及介面電位分析 36 4.2.1.1.2 mRNA有效包覆率測定 40 4.2.1.2 脂質複合奈米粒子之體外試驗 41 4.2.1.2.1 細胞存活率 41 4.2.1.2.2 細胞轉染效率 42 4.2.1.2.3 表達綠色螢光蛋白之細胞螢光影像 46 4.2.1.2.4 以倒立式共軛焦顯微鏡拍攝之細胞螢光影像 49 4.2.2 脂質/魚精蛋白複合奈米粒子 51 4.2.2.1 脂質/魚精蛋白複合奈米粒子之基本性質鑑定 51 4.2.2.1.1 粒徑及介面電位分析 51 4.2.2.2 脂質/魚精蛋白複合奈米粒子之體外試驗 53 4.2.2.2.1 細胞存活率 53 4.2.2.2.2 細胞轉染效率 54 4.2.2.2.3 表達綠色螢光蛋白之細胞螢光影像 55 4.3 綜合討論 56 第五章 結論 57 參考文獻 59 | - |
dc.language.iso | zh_TW | - |
dc.title | 開發脂質複合奈米粒子之mRNA載體平台 | zh_TW |
dc.title | Developing an mRNA Carrier Platform of Lipid Hybrid Nanoparticles | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 鍾次文;黃意真 | zh_TW |
dc.contributor.oralexamcommittee | Tze-Wen Chung;Yi-Cheng Huang | en |
dc.subject.keyword | 信使核糖核酸,載體平台,脂質複合奈米粒子,疫苗,基因治療, | zh_TW |
dc.subject.keyword | mRNA,carrier platform,lipid hybrid nanoparticle,vaccine,gene therapy, | en |
dc.relation.page | 67 | - |
dc.identifier.doi | 10.6342/NTU202301548 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2023-07-14 | - |
dc.contributor.author-college | 工學院 | - |
dc.contributor.author-dept | 醫學工程學系 | - |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf 目前未授權公開取用 | 6.9 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。